Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01457352 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of SPARC0921 in Subjects With Spasticity
A Phase 3 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 392
- Enrollment target
NCT01457352 is a Phase 3 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 392 participants.
The verdict
NCT01457352, a Phase 3 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 392 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether SPARC0921 demonstrate efficacy and safety in the treatment of spasticity.
Interventions
- DRUG SPARC0921
- DRUG Placebo0921
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2012-11-14 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01457352
The ClinicalTrials.gov registry entry for NCT01457352 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 392 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SPARC0921 is the first listed.
NCT01457352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01457352 about?
NCT01457352 is a clinical study titled "Efficacy and Safety of SPARC0921 in Subjects With Spasticity". The purpose of this study is to assess whether SPARC0921 demonstrate efficacy and safety in the treatment of spasticity.
What is the current status of trial NCT01457352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 392 participants. The study started on 2012-11-14. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT01457352?
The interventions under investigation include: SPARC0921 (DRUG), Placebo0921 (DRUG).
Who is sponsoring clinical trial NCT01457352?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.